V plex human total tau kit k151lae

Manufactured by Mesoscale

Sourced in United States

The V-PLEX Human Total Tau Kit (K151LAE) is a multiplex immunoassay designed to quantitatively measure total tau protein in human biological samples. The kit utilizes electrochemiluminescence detection technology to provide accurate and sensitive measurements of total tau levels.

Automatically generated - may contain errors

Lab products found in correlation

V plex aβ peptide panel 1 6e10 kit, by Mesoscale (4 mentions) Innotest phospho tau 181p, by Fujirebio (2 mentions) Innotest phospho tau 181p kit, by Fujirebio (1 mentions)

Spelling variants of this product

K151LAE (3 citations)

4 protocols using v plex human total tau kit k151lae

CSF Biomarker Analysis for Alzheimer's Diagnosis

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

AD biomarkers were determined using commercially available kits according to vendor specifications: V-PLEX Aβ Peptide Panel 1 (6E10) Kit (K15200E) and V-PLEX Human Total Tau Kit (K151LAE) (Mesoscale Diagnostics LLC, Rockville, USA), and Innotest Phospho-Tau(181P) (81581; Fujirebio Germany GmbH, Hannover, Germany). Cutoff values for normal and abnormal concentrations of Aβ42 (<496 pg/ml) and for the ratio Aβ42/Aβ40 (< 0.09) were derived from the literature, which applied the respective assays [21 (link)]. We used cutoff values established locally (Bonn) based on clinical nonimpaired control samples for Tau (> 470 pg/ml) and pTau (> 57 pg/ml).
In addition, we calculated the Hulstaert formula to define an abnormal Aβ42/Tau ratio [22 (link)]:

A β 42 / [240 + 1.18 \times Tau] < 1 .

This formula has been shown to be a very robust indicator of AD pathology in several independent studies (e.g., [23 (link)]). The overall CSF sampling rate in DELCODE is around 50%. Here, we report data on 144 participants. The subsample of participants with CSF differed neither in demographic variables (sex, age, years of education) nor the MMSE from the subsample without CSF.

Jessen F., Spottke A., Boecker H., Brosseron F., Buerger K., Catak C., Fliessbach K., Franke C., Fuentes M., Heneka M.T., Janowitz D., Kilimann I., Laske C., Menne F., Nestor P., Peters O., Priller J., Pross V., Ramirez A., Schneider A., Speck O., Spruth E.J., Teipel S., Vukovich R., Westerteicher C., Wiltfang J., Wolfsgruber S., Wagner M, & Düzel E. (2018). Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE). Alzheimer's Research & Therapy, 10, 15.

+ Open protocol

+ Expand

Standardized Biomarker Assessments in AD

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

CSF samples were collected from all 21 participants. More details of the assessment are reported by Jessen et al. (2018 (link)). AD biomarkers were determined centrally at the Bonn site using commercially available kits according to vendor specifications (V-PLEX Aβ Peptide Panel 1, 6E10 Kit, K15200E and V-PLEX Human Total Tau Kit, K151LAE, Mesoscale Diagnostics; and Innotest Phospho Tau(181P), 81581, Fujirebio Germany). CSF samples were tested in duplicates with a coefficient of variance < 20%. An internal control sample was used with each assay plate to ensure the general performance of the assay and that results are within the correct range. The laboratory furthermore participates in the Alzheimer's Association Quality Control program for AD biomarkers ensuring continuity of test results.

Berron D., Cardenas-Blanco A., Bittner D., Metzger C.D., Spottke A., Heneka M.T., Fliessbach K., Schneider A., Teipel S.J., Wagner M., Speck O., Jessen F, & Düzel E. (2019). Higher CSF Tau Levels Are Related to Hippocampal Hyperactivity and Object Mnemonic Discrimination in Older Adults. The Journal of Neuroscience, 39(44), 8788-8797.

+ Open protocol

+ Expand

Biomarker Characterization in DELCODE

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

In a subset of n = 317, AD biomarker information obtained at the baseline investigation was available. Commercially available kits according to vendor specifications were used: V-PLEX Aβ Peptide Panel 1 (6E10) Kit (K15200E) and V-PLEX Human Total Tau Kit (K151LAE) (Mesoscale Diagnostics LLC, Rockville, USA), and Innotest Phospho-Tau(181P) (81,581; Fujirebio Germany GmbH, Hannover, Germany). Samples from all DELCODE sites were analyzed centrally in the laboratory of the DZNE in Bonn.
The cutoffs for normal and abnormal concentrations of Aß42 (< 496 pg/ml) and for the ratio Aß42/Aß40 (< 0.09) were derived from the literature, which applied to the respective assays [25 (link), 38 (link)]. The cutoff values for tau (> 470 pg/ml) and p-tau (> 57 pg/ml) were established locally (Bonn) based on clinical non-impaired control samples.

Sannemann L., Schild A.K., Altenstein S., Bartels C., Brosseron F., Buerger K., Cosma N.C., Fliessbach K., Freiesleben S.D., Glanz W., Heneka M.T., Janowitz D., Kilimann I., Kobeleva X., Laske C., Metzger C.D., Munk M.H., Perneczky R., Peters O., Polcher A., Priller J., Rauchmann B., Rösch C., Rudolph J., Schneider A., Spottke A., Spruth E.J., Teipel S., Vukovich R., Wagner M., Wiltfang J., Wolfsgruber S., Duezel E, & Jessen F. (2020). Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study. Alzheimer's Research & Therapy, 12, 131.

+ Open protocol

+ Expand

Multiplex Biomarker Quantification in CSF

Check if the same lab product or an alternative is used in the 5 most similar protocols

For AD core biomarkers, we used the V-PLEX Aβ Peptide Panel 1 (6E10) Kit (K15200E) and the V-PLEX Human Total Tau Kit (K151LAE) (Mesoscale Diagnostics LLC, Rockville, MD, USA), as well as the INNOTEST PHOSPHO TAU(181P) kit (81581, Fujirebio, Ghent, Belgium). For inflammation-associated proteins, detailed information is provided in Additional file 1.
In the initial evaluative step, all inflammatory markers were classified as detectable, undetectable, or borderline. The last group contained markers at detection limits for which test results suggested that addition of a known dose of protein to the sample could be used to improve the assay signal (spike-in concept). A full record of this test phase is provided in Additional file 1.
CSF samples saved strictly for research purposes had been snap-frozen in liquid nitrogen and stored in a biobank at −80 °C. Prior to assay, samples were thawed on ice and divided into aliquots (total of two freeze-thaw cycles). All further sample processing was conducted on ice until samples were applied to the assays. Samples and calibrators were run in duplicates, and samples with a coefficient of variation (CV) > 20% were repeated. To normalize for interrun variance, a pooled and aliquoted CSF sample was run as an internal standard on each assay plate.

Brosseron F., Traschütz A., Widmann C.N., Kummer M.P., Tacik P., Santarelli F., Jessen F, & Heneka M.T. (2018). Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease. Alzheimer's Research & Therapy, 10, 25.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!